RobakT., Lech-MarandaE., KoryckaA., RobakE.: Purine analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chemistry, 13: 3165–3189, 2006.
2.
KeatingM.J., O'BrienS., RobertsonL.E., KantarjianH., DimopoulosM., McLaughlinP., CabanillasF., GregoireV., Ying-YangL., GandhiV., EsteyE., PlunkettW.: The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma, 14(Suppl 2): 11–16, 1994.
3.
KeatingM.J., O'BrienS., LernerS., KollerC., BeranM., RobertsonL.E., FreireichE.J., EsteyE., KantarjianH.: Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood, 92: 1165–1171, 1998.
FrohmanE.M., RackeM.K., RaineC.S.Multiple sclerosis. The plaque and its pathogenesis. N Engl J Med, 354: 942–955, 2006.
6.
DavisJCJr, FesslerB.J., TassiulasI.O., McInnesI.B., YarboroC.H., PillemerS., WilderR., FleisherT.A., KlippelJ.H., BoumpasD.T.: High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis. J Rheumatol, 25: 1694–1704, 1998.
7.
RabusinM., AndolinaM., MaximovaN., LeporeL., ParcoS., TuveriG., JankovicG.: Immunoablation followed by autologous hematopoietic stem cell infusion for the treatment of severe autoimmune disease. Haematologica, 85(Suppl 1): 81–85, 2000.
